Loading clinical trials...

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy | Clinical Trials | Clareo Health

COMPLETEDPhase 1/2NCT01207908

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).

Lead sponsor: Children's Hospital Medical Center, Cincinnati•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITING

A Remote Study Using Technology to Assess Outcomes in DMD

NCT07423026 · Duchenne Muscular Dystrophy (DMD)

RECRUITINGPhase 3

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

NCT07160634 · Duchenne Muscular Dystrophy

RECRUITINGPhase 1

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

NCT06817382 · Duchenne Muscular Dystrophy

RECRUITING

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

NCT06839469 · Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)

RECRUITINGPhase 1/2

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

NCT07037862 · Duchenne Muscular Dystrophy (DMD)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 20, 2021Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment44

Start dateNov 2010

Last updatedJan 20, 2021

Condition

Duchenne Muscular Dystrophy

Locations shown

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2021Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions